抗PD-1治疗相关白癜风样病变在临床和生物学上不同于白癜风
本研究通过8例接受抗PD-1治疗的转移性肿瘤患者与30例白癜风对照,发现白癜风样病变局限于曝光部位,呈多发斑点状脱失且无同形反应,患者无个人或家族自身免疫病史,血清CXCL10升高,皮肤CD8+T细胞浸润并表达CXCR3、产生高水平IFN-γ和TNF-α,提示其机制不同于经典白癜风。
要点
- 抗PD-1相关白癜风样病变多位于曝光部位,呈多发斑点状脱失,无同形反应。
- 患者通常无个人或家族白癜风、甲状腺炎或其他自身免疫性疾病史。
- 血清CXCL10升高,皮肤CD8+T细胞表达CXCR3并产生高水平IFN-γ和TNF-α。
核心结论
- 抗PD-1治疗相关白癜风样病变的临床和生物学模式不同于白癜风,提示不同机制。
研究设计与样本
- 病例系列研究,纳入8例接受抗PD-1治疗的转移性肿瘤患者和30例白癜风对照。
- 分析临床特征和照片,部分患者获取皮肤和血液样本,结果与白癜风组比较。
主要发现
- 所有患者病变局限于曝光部位,呈多发斑点状脱失且无同形反应。
- 患者无个人或家族白癜风、甲状腺炎或其他自身免疫性疾病史。
- 患者血清CXCL10水平升高,皮肤浸润CD8+T细胞表达CXCR3并产生高水平IFN-γ和TNF-α。
临床怎么用
- 皮肤科医生应识别抗PD-1治疗相关白癜风样病变的独特临床模式,避免误诊为经典白癜风。
- 关注曝光部位的多发斑点状脱失且无同形反应,并询问自身免疫病史。
局限性
- 本研究为单中心横断面研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The use of anti-programmed cell death (PD)-1 therapies in metastatic tumors is associated with cutaneous side effects including vitiligo-like lesions. OBJECTIVE: We sought to characterize clinically and biologically vitiligo-like lesions occurring in patients receiving anti-PD-1 therapies by studying a case series of 8 patients with metastatic tumors and 30 control subjects with vitiligo. METHODS: Eight patients receiving anti-PD-1 therapies with features of vitiligo-like lesions seen in our department were recruited. Clinical features and photographs were analyzed. For some patients, skin and blood samples were obtained. Results were compared with the vitiligo group. RESULTS: All patients developed lesions localized on photoexposed areas with a specific depigmentation pattern consisting of multiple flecked lesions without Koebner phenomenon. In contrast to vitiligo, patients receiving anti-PD-1 therapies who developed vitiligo-like lesions did not report any personal or family histories of vitiligo, thyroiditis, or other autoimmune disorders. Analysis of blood and skin samples revealed increased C-X-C motif ligand 10 levels in serum of patients developing vitiligo-like lesions, associated with skin infiltration of CD8 T-cells expressing C-X-C motif receptor 3 and producing elevated levels of interferon-γ and tumor necrosis factor-alfa. LIMITATIONS: This cross-sectional study concerned a single center. CONCLUSIONS: Clinical and biological patterns of vitiligo-like lesions occurring in patients receiving anti-PD-1 therapies differ from vitiligo, suggesting a different mechanism.
引用
- Larsabal M, Marti A, Jacquemin C, et al. Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo. J Am Acad Dermatol. 2017. PMID: 28094061. doi:10.1016/j.jaad.2016.10.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。